B cell non-Hodgkin's lymphoma: experience from a tertiary care cancer center

Annals of Hematology
Gaurav PrakashB K Mohanti

Abstract

Information on presentation and outcome of B cell non-Hodgkin's lymphoma (B-NHL) is limited from developing countries. Data of newly diagnosed adult aggressive B-NHL (n = 260) patients were analyzed for clinical presentation, histological subtype, response to therapy, and survival. Univariate and multivariate Cox-regression analyses were performed for identification of prognostic factors. Diffuse large B cell lymphoma was the most common subtype (71 %). Median age was 50 years (18-78 years). The most common symptom was peripheral lymphadenopathy seen in 66 % of cases. Forty-seven percent of patients had advanced stage (stage III/IV), and 41 % had ECOG performance status of II-IV. B symptoms and bulky disease were present in 47 and 26 %, respectively. Intermediate to high risk score according to the International Prognostic Index (IPI) was seen in 67 %. Cyclophosphamide, adriamycin, vincristine, and prednisolone (CHOP) and CHOP-like regimens were used in 70 % cases, while R-CHOP was used in 18 % cases. For diffuse large B cell lymphoma (DLBCL) patients, in intent-to-treat analysis, the overall response and complete remission rates were 73 and 60 %, respectively. Four-year event-free and overall survival was 54 and 64.7 %, respec...Continue Reading

References

Sep 30, 1993·The New England Journal of Medicine·UNKNOWN International Non-Hodgkin's Lymphoma Prognostic Factors Project
Sep 18, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J R AndersonD D Weisenburger
Nov 26, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M JerkemanM Akerman
Mar 9, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K N NareshC S Soman
Dec 17, 2002·Medical Oncology·Manisha BhutaniVinod Kochupillai
Jan 13, 2004·Clinical Lymphoma·Brian C H Chiu, Dennis D Weisenburger
Mar 23, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J J TurnerB Armstrong
Nov 14, 2007·Journal of Cancer Research and Therapeutics·Rajiv Sarin
Jan 1, 1990·Leukemia & Lymphoma·S H AdvaniD N Rao

❮ Previous
Next ❯

Citations

Nov 5, 2016·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Gaurav PrakashSubhash Varma
Sep 14, 2019·Journal of Oral and Maxillofacial Pathology : JOMFP·Aashka SethiIqbal Singh
Apr 7, 2018·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Gaurav PrakashSubhash Varma
Aug 22, 2018·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Reena NairVivek Radhakrishnan
Aug 8, 2018·Infectious Agents and Cancer·Luis Ernesto CuellarKaren Marie Winkfield
Aug 17, 2018·South Asian Journal of Cancer·Ajay GogiaSoumya Mallick

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.